NextCure Inc (NXTC) - Total Liabilities
Based on the latest financial reports, NextCure Inc (NXTC) has total liabilities worth $15.97 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is NextCure Inc growing its equity to track the company's year-over-year net asset growth rate.
NextCure Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how NextCure Inc's total liabilities have evolved over time, based on quarterly financial data. See NextCure Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
NextCure Inc Competitors by Total Liabilities
The table below lists competitors of NextCure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Relpol SA
WAR:RLP
|
Poland | zł36.29 Million |
|
Synertec Corporation Ltd
AU:SOP
|
Australia | AU$12.76 Million |
|
Havsfrun Investment AB (publ)
ST:HAV-B
|
Sweden | Skr1.53 Million |
|
LQwD FinTech Corp
V:LQWD
|
Canada | CA$42.45K |
|
TIALIS ESSENTIAL IT PLC
F:U6M
|
Germany | €11.21 Million |
|
A1 Investments & Resources Ltd
AU:AYI
|
Australia | AU$317.73K |
|
Sh E & Chemical Co. Ltd.
KO:002360
|
Korea | ₩31.38 Billion |
|
Harta Djaya Karya Tbk Pt
JK:MEJA
|
Indonesia | Rp25.12 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down NextCure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NextCure Inc (NXTC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NextCure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NextCure Inc (2017–2024)
The table below shows the annual total liabilities of NextCure Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $15.39 Million | +13.01% |
| 2023-12-31 | $13.62 Million | -18.12% |
| 2022-12-31 | $16.63 Million | +84.79% |
| 2021-12-31 | $9.00 Million | -30.36% |
| 2020-12-31 | $12.92 Million | -62.74% |
| 2019-12-31 | $34.68 Million | -82.17% |
| 2018-12-31 | $194.57 Million | +343.43% |
| 2017-12-31 | $43.88 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more